Nuwellis Appoints Mike McCormick Chief

Nuwellis announced a leadership change on June 16, 2026. Nuwellis appointed former board director Mike McCormick as CEO, effective June 30, 2026, as John Erb transitions from his executive role and continues as Chairman.

What changed

Mike McCormick was named Chief Executive Officer. John Erb, who served as President, CEO, and Chairman of the Board, will transition from his executive leadership role and continue serving as Chairman of the Board.

Leader: Mike McCormick
Role: Chief Executive Officer
Effective: June 30, 2026
Announcement date: June 16, 2026

Leadership background

McCormick is a medical technology executive with more than three decades of leadership experience spanning product development, commercialization, corporate strategy, and value creation. He served as a Board Member and Independent Director of Nuwellis from June 2023 through January 2026. The company said he has founded, scaled, and led both public and private medical technology companies across multiple healthcare markets.

The mandate

In the announcement, McCormick said he is excited to work with employees, the leadership team, the Board, clinicians, and customers to build on the company’s momentum, strengthen commercial execution, and advance its pipeline. He also said Nuwellis has an opportunity to expand the role of precision fluid management in cardiorenal care.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Nuwellis